If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Taltz Summary of Product Characteristics (SmPC)
Taltz® ▼ (ixekizumab): Switching from Ixekizumab to a Different Biologic Treatment
Switching from ixekizumab to a different biologic has not been studied by Eli Lilly and Company.
from ixekizumab to a different biologic, including to a TNF
inhibitor, has not been studied by Lilly in clinical trials.
Guidelines on Biologic Switching
recommendations on switching from ixekizumab to another biologic are
Joint American Academy of Dermatology and National Psoriasis
Foundation 2019 guidelines on the treatment and management of
psoriasis with biologics states no evidence-based studies have been
conducted to determine the appropriate duration of time between
discontinuation of the previous medication and initiation of a
biologic. The guidelines suggest assessments should be done on a
case-by-case basis considering many factors including
to previous treatment, and
expert opinion (some experts will begin administration of the new
biologic as soon as it is available; whereas, others may wait 3 to
4 half-lives of the previous therapy before beginning the new
British Association of Dermatologists 2017 psoriasis guidelines for
biologic therapies include to consider using a washout period of 1
month or the length of a treatment cycle (whichever is longer) when
transitioning between biologic therapies.2
Transitioning Therapies programme consensus published in 2014
recommends when switching from one biologic therapy to another to
include the use of a washout period if the switch is made due to an
AE and do not include a washout period if the switch is made due to
a lack of efficacy. Initiation of the second biologic therapy occurs
with the usual induction and maintenance dosages.3
Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of
care for the management and treatment of psoriasis with biologics. J
Am Acad Dermatol. 2019;80(4):1029-1072.
Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of
Dermatologists guidelines for biologic therapy for psoriasis 2017. Br
J Dermatol. 2017;177:628-636. http://dx.doi.org/10.1111/bjd.15665
Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on
appropriate treatment optimization and transitioning in the
management of moderate-to-severe plaque psoriasis. J Eur Acad
Dermatol Venereol. 2014;28(4):438-453.
= Eli Lilly and Company
= tumor necrosis factor
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:March 21, 2019
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at email@example.com